Selva Group

Selva Therapeutics is a clinical-stage biotechnology company focused on developing small molecule antiviral therapies for infectious diseases with high unmet medical needs. The company's lead candidate, SLV213 (also known as K777), is a potent inhibitor of host cell cysteine proteases, specifically cathepsin L, which is critical for the entry of several viruses into human cells. Selva is advancing SLV213 for the treatment of COVID-19 and Ebola virus disease, leveraging its mechanism to prevent viral replication and disease progression. The company was founded by experienced industry veterans and has received support from government grants and private investors to progress its pipeline through clinical development.